Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275204 | 1.00 | DPP4 (0.37) | DPP4ALDH1A1TSHRGLI1BCHE | |
| SCHEMBL4760467 | 0.84 | DPP4 (0.34) | DPP4ALDH1A1TSHRGLI1BCHE | |
| SCHEMBL2329823 | 0.84 | ALDH1A1 (0.42) | DPP4ALDH1A1TSHRGLI1BCHE | |
| SCHEMBL6735237 | 0.84 | ALDH1A1 (0.42) | DPP4ALDH1A1TSHRGLI1BCHE | |
| SCHEMBL22042408 | 0.83 | MME (0.31) | — | |
| SCHEMBL4760487 | 0.81 | BCHE (0.36) | DPP4GLI1BCHE | |
| Hydrochloric Acid SCHEMBL2378323 | 0.79 | BCHE (0.36) | DPP4GLI1BCHE | |
| SCHEMBL1543311 | 0.78 | GLI1 (0.35) | DPP4GLI1BCHE | |
| SCHEMBL4103676 | 0.78 | GLI1 (0.35) | DPP4GLI1BCHE | |
| SCHEMBL4760474 | 0.78 | GLI1 (0.35) | DPP4GLI1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-25 | — | — | US | disclosed |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-8629133-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| WO-2012121361-A1 | DISPIROPYRROLIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | DPP4 2270/4885ALDH1A1 1254/4885TSHR 3559/4885 |
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | DPP4 4192/4885ALDH1A1 2383/4885TSHR 1670/4885 |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TPD52L2 | DPP4 2001/4885ALDH1A1 1173/4885TSHR 3700/4885 |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | DPP4 2270/4885ALDH1A1 1254/4885TSHR 3559/4885 |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | DPP4 2270/4885ALDH1A1 1254/4885TSHR 3559/4885 |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | DPP4 2270/4885ALDH1A1 1254/4885TSHR 3559/4885 |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | DPP4 282/4885ALDH1A1 276/4885TSHR 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.